CSN Login
Members Online: 11

Is there hope?

Glad to be done's picture
Glad to be done
Posts: 558
Joined: Jul 2012

A friend of mine posted this story below on Facebook

ISRAEL FIGHTS CANCER: An Exclusive Report by United with Israel

Dr. Lior Carmon at Vaxil's lab in Nes Ziona, Israel

(Nes Ziona, ISRAEL) An Israeli company is developing a new cancer drug which aims to stop cancer from coming back.

Every year millions of people are diagnosed with cancer worldwide. Although modern medicine has made huge progress in treating this disease, what often happens is that the cancer is treated and the patient goes into remission or is even “cured” – but then it becomes a waiting game to see if the cancer comes back.

Imagine if there was a new treatment option that would stop cancer from returning!

An Israeli medical team is attempting to do just that, to offer a new treatment with the potential for long-term maintenance – to stop the cancer from coming back.

Vaxil is a clinical stage biotechnology company based in Israel which develops therapeutic vaccines to treat cancer and infectious diseases. Therapeutic vaccines seek to harness the patient’s immune system to attack and destroy cancer cells.

The therapeutic vaccine educates the immune system to seek out and destroy those cells which display cancer “markers” and to leave the healthy cells untouched. This means that the treatment has very few side effects, unlike other conventional treatments. This safety profile also means that it is suitable for long-term maintenance therapy.

Vaxil’s lead product, ImMucin, aims to teach the immune system of the cancer patient to attack those cancer cells which display the protein “MUC1″. Since MUC1 appears on 90% of all cancer cellss, ImMucin has a potentially broad application to many different strands of cancer such as lung, breast, kidney, prostate, ovarian, pancreatic and colon cancer – and even to hematological cancers such as leukemia, lymphomas and myeloma.

ImMucin is currently being evaluated in a Phase I/II clinical trial in patients with Multiple Myeloma (a blood cancer). All patients enrolled are in a stage process whereby the disease is coming back after a period of remission.

The clinical trial is being conducted at Hadassah University Hospital in Jerusalem and at the Rambam Medical Center in Haifa.

Hadassah University Hospital Ein Kerem in Jerusalem

The trial is expected to be completed by the end of the year, and will involve 15 patients. Future trials are planned in Israel and abroad and will have larger number of participants.

Interim results on half of the trial subjects enrolled (7 out of 15 patients) were released last April and were very encouraging. There were no serious side effects and all ImMucin-treated patients induced a strong immune response.

Moreover, out of the seven patients analyzed, three re-attained a stage of complete response, meaning that the disease progression was stopped and there was no longer any detectable cancer. Final results from this trial are expected at the beginning of next year. The team is also conducting a follow up study of patients who have completed their treatment with ImMucin and do not require further treatments.

Vaxil’s founder and CEO is Lior Carmon, PhD., MBA. Dr. Carmon is an expert in the fields of immunology and cancer. After earning his PhD from the Weizmann Institute, Dr. Carmon founded and managed several Israeli biotech companies. He was joined by Julian Levy M.A., who acts as Vaxil’s President and CFO. Mr. Levy is a Cambridge educated lawyer, who immigrated to Israel England and is a seasoned biotechnology entrepreneur with extensive experience in early stage biotech companies.

Dr. Carmon notes that “A key advantage of Vaxil’s vaccines is that they can induce a comprehensive and divest immune response without need for an adaptation to the individual’s type of immune systems. Every patient has a unique immune system. Thus, many therapeutic vaccines are suitable only for a proportion of the potential patient population. Results obtain so far has shown that ImMucin can initiate strong and diversified immune response in all patients, irrespective of their immune system. This is not trivial.” Moreover, unlike many other products “our vaccines are design to try and deal with the tumor’s tendency to evade the immune response. We believe that this is a critical factor for success.”

Although Vaxil’s main interest is therapeutic vaccines, its research team has shown that the scope of the company’s VaxHit technology is very broad and may include new areas such as diagnostics. Earlier this year the company published an article describing the discovery of naturally generated antibodies in cancer patients with myeloma. By detecting and following the levels of these antibodies, it may be possible to determine the likelihood of patients developing cancer in the future.

Reported by Joseph Sherman, United with Israel

2timothy1 7's picture
2timothy1 7
Posts: 336
Joined: Jan 2012

Thanks for posting it for us! It gives all of us hope for a cure someday.

Hissy_Fitz's picture
Hissy_Fitz
Posts: 1869
Joined: Sep 2009

More than one research physcian feels that vaccines are the best "road" to vanquish Cancer. Dr Paul Sabbatini at Memorial Sloan Kettering told me that he is convinced of this.

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network